Replies to post #399644 on NorthWest Biotherapeutics Inc (NWBO)

[anders2211]

Oohw now I understand you mean this March 1 loan
https://www.sec.gov/ix?doc=/Archives/edgar/data/1072379/000110465921032416/tm218804d1_8k.htm

Well, it doesn't say that the loan is due before Nov 1 if no TLD or any other event did not happen at a certain date. If it were to be due on Oct 5 if a certain set of events did not happen then that ought to have been disclosed by Northwest. Like us, the company that loaned the amount to NWBO is probably watching the financial status, SP, and disclosure of TLD by NWBO like a hawk, just like us.

Nice grapple, you can get a good bite out of probably anything with that machine :)

On March 1, 2021, Northwest Biotherapeutics, Inc. (the “Company”) entered into a Commercial Loan Agreement and Note (collectively, the “Loan Agreement”) with Streeterville Capital, LLC (the “Holder”) in the amount of $11,005,000. The Loan Agreement has a maturity of 22 months. Repayments do not start until November 1, 2021.

Following November 1, 2021, the Loan Agreement will be amortized in 14 equal monthly installments of principal at 110% of the pro rata amount, plus accrued interest. Interest on the Loan Agreement accrues at a rate of 8% per annum, and the Loan Agreement includes an original issue discount of ten percent. The Loan Agreement allows pre-payment at any time at the Company’s election. If the Company elects to pre-pay, the pre-payment would include a 10% charge. The Loan Agreement contains customary default provisions, including for potential acceleration.